Global Inhalation Anesthesia Market By Product Type (Sevoflurane, Desflurane, and Isoflurane), By Application (Induction and Maintenance), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2029

Report Code: PMI4518 | Publish Date: March 2021 | No. of Pages: 160

Global Inhalation Anesthesia Market By Overview

An inhalational anaesthetic is used for the induction and maintenance of general anesthesia as well as sedation.  It is a chemical compound possessing general anaesthetic properties that can be delivered via inhalation. Most common inhalational anaesthetics are sevoflurane, desflurane, and nitrous oxide.

 

Global Inhalation Anesthesia Market By Dynamics

Increasing number of surgeries involving anesthesia, better patient outcomes resulting from inhalation anesthesia as compared to intravenous variants, increasing need to reduce hospital care cost across the globe are major drivers of the global inhalation anesthesia market. In addition, other factors such as increasing geriatric population prone to chronic diseases, and increasing accessibility to health services are some among the major factors contributing to growth of the target market. Furthermore, advantages of the product such as efficient control over sedation, short duration of action, and predictable nature of the product have led to its adoption among surgeons as well as patients, are drivers thereby fuelling growth of the global inhalation anesthesia market.

Increasing adoption of the product in veterinary field is an ongoing trend observed in the target market, and is expected to further fuel the target market growth. However, generic competition for almost all of the halogenated agents and recent patent expiries are also restraining the inhalation anesthetics market growth. 

Global Inhalation Anesthesia Market By Segmentation

Global inhalation anesthesia market has been segmented into product type, application, and region.

On the basis of product type, global inhalation anesthesia market has been bifurcated into sevoflurane, desflurane, and isoflurane. Sevoflurane product type segment is dominating in the target market so far attributing to its high preference and suitable for children and adults for maintenance as well as induction. 

According to application, global market is segmented into induction and maintenance. Maintenance sub-segment has held the largest revenue so far, due to its higher volume consumption. Induction segment may witness considerable growth over the forecast period due to its properties such as preservation of impulsive ventilation and redistribution throughout apnea; it is also used for inhalation induction in respiratory airway problems.

Based on region, the global inhalation anesthesia market is segmented into North America, Latin America, Europe, Middle East, Asia-Pacific, and Africa. Currently, North America is leading the target market, followed by Europe. Increasing number of plastic surgeries along with increasing prevalence of the chronic lower respiratory disease in these regions will fuel adoption of inhalation anesthesia over the forecast period.

Developing economies such as India, South Africa, Brazil, and China are expected to witness a rise in target market growth over the coming years owing to factors such as large surgical patient pool, developing healthcare infrastructure, and rising healthcare tourism. 

Global Inhalation Anesthesia Market By Key Players

Key players operating in the global inhalation anesthesia market include Baxter International Inc., AbbVie, Inc., Piramal Healthcare, Lunan Pharmaceuticals Co., Ltd., Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd., Fresenius Kabi AG, Halocarbon Products Corporation. 

FAQs

Global inhalation anesthesia market has been segmented into product type, application, and region.

Increasing adoption of the product in veterinary field is an ongoing trend observed in the target market, and is expected to further fuel the target market growth. However, generic competition for almost all of the halogenated agents and recent patent expiries are also restraining the inhalation anesthetics market growth.

North America is leading the target market, followed by Europe. Increasing number of plastic surgeries along with increasing prevalence of the chronic lower respiratory disease in these regions will fuel adoption of inhalation anesthesia over the forecast period.

Key players operating in the global inhalation anesthesia market include Baxter International Inc., AbbVie, Inc., Piramal Healthcare, Lunan Pharmaceuticals Co., Ltd., Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd., Fresenius Kabi AG, Halocarbon Products Corporation.